The CHMP adopted an extension to an existing indication as follows: Mounjaro is indicated for the treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise
11 dicembre 2025
Leggi
Wang Y, Ram J, Bianchi, C et al.
Diabetologia. Pub. online 12 Dec 2025.
Leggi
Beck RW, Hirsch IB, Raghinaru D, et al.
Diabetes Care. Pub. online 5 Dec 2025.
Leggi
Wang Y, Wang S, Wang W, et al.
Diabetes Obes Metab. Pub. online 4 Dec 2025.
Leggi
Schoenaker D, Dyer E, Heslehurst N, et al.
Diabet Med. Pub. online 7 Dec 2025.
Leggi
Ardakani J, Shahid I, Gullapelli R, et al.
JAMA Netw Open. Pub. online 1 Dec 2025.
Leggi
Brinkmann MLS, Krasilnikoff NJ, Chaaban MA, et al.
Diabet Med. Pub. online 7 Dec 2025.
Leggi
Chou YC, Weng SH, Cheng FS, et al.
Diabetes Obes Metab. Pub. online 5 Dec 2025.
Leggi
Agboghoroma OF, Heier KR, Atac O, et al.
BMJ Open Diabetes Res Care. Pub. online 3 Dec 2025.
Leggi
Nakada K, Tanaka K, Kimura H, et al.
BMJ Open Diabetes Res Care. Pub. online 3 Dec 2025.
Leggi
